05 June – Targeted treatments for urological cancers

Thursday 05 June, Christie Hospital, Manchester

1-day course: Targeted Treatments for Urological Cancers

Level: Intermediate/advanced (Designed for research nurses, junior doctors and other staff working on cancer trials for urological cancers; requires some prior understanding of cancer biology)

Description: This course provides a description of the faulty genes and proteins that drive prostate, kidney, bladder and testicular cancer. It also provides an overview of targeted treatment approaches for these diseases, such as hormone therapy, immunotherapy, kinase inhibitors and angiogenesis inhibitors. The relevant science behind each treatment is explained for a non-scientific, non-specialist audience.

To book, contact: education.events@christie.nhs.uk

Programme

A few important principles:
  • The role of DNA damage & epigenetics in cancer development
  • Cancer cells and their microenvironment
  • Genetic instability and intra-tumoural heterogeneity: new enemies
  • MAbs and kinase inhibitors: spot the difference
Introducing prostate cancer
  • Cellular, molecular and genetic makeup
  • Interaction between the androgen receptor and other signalling pathways
Targeted treatments for prostate cancer
  • Hormone therapies: old and new inhibitors of androgens and androgen receptor signalling (eg. LHRH agonists & antagonists, MDV3100 & enzalutimide, abiraterone)
  • Novel targets: EGFR, IGF-1R, PDGFR, angiogenesis, HSP90
  • Targeting the bone: radium223, denosumab, MET inhibitors
Introducing kidney cancer
  • Introducing  the main subtypes of renal cell carcinoma: clear cell, papillary (types 1 and 2) and chromophobe
  • Genetic mutations and signalling pathways associated with different types
Targeted treatments for kidney cancer
  • Clear-cell RCC: Angiogenesis inhibitors (eg. sunitinib, sorafenib, pazopanib, bevacizumab, axitinib, tivozanib, regorafenib, dovitinib); mTOR inhibitors (everolimus, temsirolimus, ATP-competitors)
  • Papillary RCC: MET inhibitors (AMG102, foretinib); VEGF and mTOR inhibitors
  • Chromophobe RCC:  a role for mTOR, KIT and HER2 inhibitors?
Immunotherapy approaches for urological cancers
  • The science behind passive and active immunotherapy and immune-modulators
  • Drugs covered include: sipileucel-T, ipilimumab, nivolumab, lambrolizumab
Targeted treatments for bladder cancer, testicular cancer and penile cancer
  • Molecular defects and an overview of targeted treatment approaches